Sugi Predict

Sugi Predict / Compounds / SCHEMBL4383952

SCHEMBL4383952

SCHEMBL4383952

CC1(C)O[C@H](C(O)(c2ccccc2)c2ccccc2)[C@@H](C(O)(c2ccccc2)c2ccccc2)O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 1.00
▸ CYP3A4 P08684 2/20 1.00
▸ MEN1 O00255 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ CYP2C19 P33261 3/20 0.50
▸ LMNA P02545 3/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ HRH1 P35367 2/20 0.40
▸ SCN1A P35498 1/20 0.40
▸ SCN2A Q99250 1/20 0.40
▸ SCN3A Q9NY46 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ ATM Q13315 1/20 0.38
▸ CYP1A2 P05177 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ APOBEC3A P31941 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7994941 1.00 MAPK1 (1.00) MAPK1CYP3A4MEN1KMT2ACYP2C19
SCHEMBL7916942 1.00 MAPK1 (1.00) MAPK1CYP3A4MEN1KMT2ACYP2C19
SCHEMBL2504692 1.00 MAPK1 (1.00) MAPK1CYP3A4MEN1KMT2ACYP2C19
SCHEMBL2534650 1.00 MAPK1 (1.00) MAPK1CYP3A4MEN1KMT2ACYP2C19
Phosphoric Acid SCHEMBL27782171 0.91 MAPK1 (0.83) MAPK1CYP3A4MEN1KMT2ACYP2C19
SCHEMBL20702246 0.89 MAPK1 (0.80) MAPK1CYP3A4MEN1KMT2ACYP2C19
SCHEMBL19139099 0.89 CYP3A4 (0.79) MAPK1CYP3A4MEN1KMT2ACYP2C19
SCHEMBL3918350 0.89 CYP3A4 (0.79) MAPK1CYP3A4MEN1KMT2ACYP2C19
SCHEMBL16309629 0.87 CYP3A4 (0.77) MAPK1CYP3A4MEN1KMT2ACYP2C19
SCHEMBL8538968 0.82 MAPK1 (0.70) MAPK1CYP3A4MEN1KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119487009-A Process for producing enantiomer (R) configuration of triazole derivative 株式会社吴羽 2025-02-18 — — CN claimed
WO-2024014282-A1 METHOD FOR PRODUCING TRIAZOLE DERIVATIVE ENANTIOMER (R) 株式会社クレハ 2024-01-18 — — WO claimed
US-6794529-B2 CATALYTIC REACTION OF DIBORANE COMPOUND USING GROUP 8 METAL CATALYST COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2004-09-21 — — US claimed
US-6472345-B2 TITANIUM HALIDES, SULFONATES OR DIOLATES SOLVIAS AG (CH) 2002-10-29 — — US claimed
US-20020026067-A1 Catalytic halogenation of activated methylene and methine compounds SOLVIAS AG (CH) 2002-02-28 — — US claimed
EP-1151980-A1 Catalytic halogenation of activated methylene and methine compound Solvias AG (CH) 2001-11-07 — — EP claimed
US-6184404-B1 THE ORGANOZINC COMPOUND HAVING A LIGAND WHICH IS TRANSFERRED TO THE ALDEHYDE, THE OTHER LIGAND ACTS AS SO-CALLED DUMMY LIGAND; PRODUCING FUNCTIONALIZED SECONDARY ALCOHOLS IN GOOD YIELDS AND VERY GOOD ENANTIOMERIC PURITY; MATERIALS HANDLING METALLGESELLSCHAFT AKTIENGESELLSCHAFT (DE) 2001-02-06 — — US claimed
US-6090950-A Chiral hydride complexes ZEELAND CHEMICALS, INC. (US) 2000-07-18 — — US claimed
EP-0558656-B1 NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES MASSACHUSETTS INST TECHNOLOGY (US) 1996-04-17 — — EP claimed
US-5292893-A Catalytic asymmetric and non-asymmetric reduction of times and oximes using metal catalysts MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1994-03-08 — — US claimed
EP-0558656-A1 NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES. MASSACHUSETTS INST TECHNOLOGY (US) 1993-09-08 — — EP claimed
US-5227538-A Silane, chiral additive MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1993-07-13 — — US claimed
WO-1992009545-A2 NEW METHODS FOR THE CATALYTIC REDUCTION OF ORGANIC SUBSTRATES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1992-06-11 — — WO claimed
JP-1075435-A — — None — — JP disclosed
JP-5059035-A — — None — — JP disclosed
EP-3694864-B1 BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF QPEX BIOPHARMA INC (US) 2025-03-05 — — EP disclosed
US-5227538-A Silane, chiral additive MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1993-07-13 — — US disclosed
JP-H0559035-A SEPARATION OF ISOMER DAICEL CHEM IND LTD 1993-03-09 — — JP disclosed
EP-0387196-A1 Complexes with optically active ligands, process for their preparation and their use CIBA-GEIGY AG (CH) 1990-09-12 — — EP disclosed
JP-S6475435-A OPTICAL RESOLUTION UBE INDUSTRIES 1989-03-22 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020026067-A1 Catalytic halogenation of activated methylene and methine compounds TET1, TPO, EMG1 MAPK1 925/4885CYP3A4 338/4885MEN1 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.